


Stabilis



Fentanyl citrate



Noms commerciaux

Anesfent	Brésil
Fendrop	Inde
Feniject	Iran
Fenodid	Chili, Colombie, Mexique
Fenstud	Autriche
Fentamed	Allemagne, Autriche, Brésil, Espagne, Italie
Fentanest	Chili, Equateur, Espagne, Italie, Mexique, Portugal
Fentanex	Colombie, Equateur, Espagne
Fentanyl	Allemagne, Arabie Saoudite, Australie, Autriche, Danemark, Luxembourg, Tunisie
Fentax	Argentine, Equateur
Filtaten	Mexique
Haldid	Danemark
Lanzapin	Colombie
Leptanal	Islande, Norvège, Suède
Miuron	Colombie
Nafluvent	Argentine, Colombie
Sintenyl	Suisse
Sublimaze	Argentine, Australie, Grande Bretagne, Irlande, Nouvelle Zélande
Talgesil	Malaisie
Talinat	Turquie
Utranil	Mexique



Stabilité des solutions

























































































































		4,55 µg/ml	22°C		48			223
PVC		4,55 µg/ml	22°C		48			223
PVC		10 & 50 µg/ml	23°C		90			4228
PVC		10 & 50 µg/ml	4°C		90			4228
PVC		20 µg/ml	23°C		30			222
PVC		20 µg/ml	3°C		30			222

		50 µg/ml	22°C		28			2031
		50 µg/ml	25°C		14			2118
		50 µg/ml	5°C		28			2031
		10 µg/ml	22°C		93			3916
		10 µg/ml	5°C		93			3916
		10 & 50 µg/ml	23°C		90			4228
		10 & 50 µg/ml	4°C		90			4228
		50 µg/ml	22°C		93			3916
		50 µg/ml	5°C		93			3916
		10 µg/ml	25°C		100			4303
		13 & 34 µg/ml	22°C		7			929
		13 & 34 µg/ml	38°C		7			929
		13 & 34 µg/ml	5°C		7			929
		20 & 40 µg/ml	23°C		90			4223
		5 µg/ml	23-27°C		90			2334
		50 µg/ml	23°C		90			4223
		50 µg/ml	22°C		28			2031
		50 µg/ml	25°C		100			4303
		50 µg/ml	5°C		28			2031



Stabilité en mélange

		25 µg/ml	15°C-30°C		Esmolol hydrochloride : 5 mg/ml	8		8
		3 µg/ml	2-8°C		Ropivacain hydrochloride : 1,5 mg/ml	51		1832
		3 µg/ml	20°C		Ropivacain hydrochloride : 1,5 mg/ml	51		1832
		10 µg/ml	25°C		Droperidol : 0,05 mg/ml Ketamine hydrochloride : 1 mg/ml	30		1993
		20 µg/ml	25°C		Naloxone hydrochloride : 0,004 mg/ml	72		4559
		20 µg/ml	4°C		Naloxone hydrochloride : 0,004 mg/ml	72		4559
		25 µg/ml	22°C-23°C		Milrinone lactate : 0,2 mg/ml	4		813
		20 & 40 µg/ml	23°C-25°C		Midazolam hydrochloride : 0,1 & 0,5 mg/ml	3		225
		25 µg/ml	25°C		Palonosetron hydrochloride : 25 µg/ml	4		2196

		3 µg/ml	2-8°C		Ropivacain hydrochloride : 1,5 mg/ml	11		1832
		3 µg/ml	20°C		Ropivacain hydrochloride : 1,5 mg/ml	11		1832
		20 µg/ml	23°C		Bupivacaine hydrochloride : 1,250 mg/ml	30		60
		10 µg/ml	25°C		Droperidol : 0,05 mg/ml Ketamine hydrochloride : 1 mg/ml	30		1993
		20 µg/ml	25°C		Naloxone hydrochloride : 0,004 mg/ml	72		4559
		2 µg/ml	25°C-30°C		Bupivacaine hydrochloride : 0,59 & 1,25 mg/ml	32		1723
		1,25 µg/ml	30°C		Bupivacaine hydrochloride : 0,43 mg/ml Epinephrine hydrochloride : 0,0006 µg/ml	48		217
		1,25 µg/ml	3°C		Bupivacaine hydrochloride : 0,43 mg/ml Epinephrine hydrochloride : 0,0006 µg/ml	20		217
		20 µg/ml	3°C		Bupivacaine hydrochloride : 1,250 mg/ml	30		60
		2 µg/ml	4-8°C		Bupivacaine hydrochloride : 0,59 & 1,25 mg/ml	32		1723
		10 µg/ml	4°C		Droperidol : 0,05 mg/ml Ketamine hydrochloride : 1 mg/ml	30		1993
		20 µg/ml	4°C		Naloxone hydrochloride : 0,004 mg/ml	72		4559
		2 µg/ml	18-22°C		Epinephrine hydrochloride : 2 µg/ml Bupivacaine hydrochloride : 1 mg/ml	184		2306
		2 µg/ml	18-22°C		Bupivacaine hydrochloride : 1 mg/ml	184		2306
		2 µg/ml	4°C		Bupivacaine hydrochloride : 1 mg/ml Epinephrine hydrochloride : 2 µg/ml	184		2306
		2 µg/ml	4°C		Bupivacaine hydrochloride : 1 mg/ml	184		2306
		1 µg/ml	30°C		Ropivacain hydrochloride : 1 & 2 mg/ml	30		1665
		10 µg/ml	30°C		Ropivacain hydrochloride : 2 mg/ml	30		1665
		2 µg/ml	22°C		Epinephrine hydrochloride : 2 µg/ml Bupivacaine hydrochloride : 1 mg/ml	180		1875
		2 µg/ml	4°C		Epinephrine hydrochloride : 2 µg/ml Bupivacaine hydrochloride : 1 mg/ml	180		1875
		3 µg/ml	2-8°C		Ropivacain hydrochloride : 1,5 mg/ml	51		1832
		3 µg/ml	20°C		Ropivacain hydrochloride : 1,5 mg/ml	51		1832
		40 µg/ml	32°C		Scopolamine N-butyl bromide : 0,85 mg/ml Midazolam hydrochloride : 0,6 mg/ml	10		1405
		40 µg/ml	32°C		Midazolam hydrochloride : 0,6 mg/ml Metoclopramide hydrochloride : 0,7 mg/ml	10		1405
		13 & 38 µg/ml	22°C		Midazolam hydrochloride : 0,66 & 0,9 mg/ml	7		929
		16,7 µg/ml	23°C		Ondansetron hydrochloride : 1,33 mg/ml	24		815
		13 & 38 µg/ml	38°C		Midazolam hydrochloride : 0,66 & 0,9 mg/ml	4		929
		16,7 µg/ml	4°C		Ondansetron hydrochloride : 1,33 mg/ml	24		815
		13 & 38 µg/ml	5°C		Midazolam hydrochloride : 0,66 & 0,9 mg/ml	7		929
		0,0024 µg/ml	22°C		Propofol : 0,0095 mg/ml Vecuronium bromide : 0,127 mg/ml	1		1863

		16 µg/ml	24°C		Hydromorphone hydrochloride : 0,08 mg/ml Nefopam : 0,8 mg/ml Ramosetron : 12 µg/ml	4		4666
		16 µg/ml	24°C		Oxycodone hydrochloride : 0,4 mg/ml Nefopam : 0,8 mg/ml Ondansetron hydrochloride : 0,32 mg/ml	4		4666
		16 µg/ml	24°C		Oxycodone hydrochloride : 0,4 mg/ml Nefopam : 0,8 mg/ml Ramosetron : 12 µg/ml	4		4666
		16 µg/ml	24°C		Hydromorphone hydrochloride : 0,08 mg/ml Nefopam : 0,8 mg/ml Ondansetron hydrochloride : 0,32 mg/ml	4		4666
		4 µg/ml	20-22 °C		Levobupivacaine hydrochloride : ? mg/ml	40		3507
		1 µg/ml	37°C		Ziconotide acetate : 25 µg/ml	26		2280
		4,1 µg/ml	20-24°C		Epinephrine hydrochloride : 2 µg/ml Levobupivacaine hydrochloride : 0,56 mg/ml	40		3401
		4,1 µg/ml	20-24°C		Levobupivacaine hydrochloride : 0,56 mg/ml	60		3401
		4,1 µg/ml	20-24°C		Epinephrine hydrochloride : 2 µg/ml Levobupivacaine hydrochloride : 0,56 mg/ml	48		3401
		4,1 µg/ml	4-8°C		Epinephrine hydrochloride : 2 µg/ml Levobupivacaine hydrochloride : 0,56 mg/ml	60		3401
		4,1 µg/ml	4-8°C		Levobupivacaine hydrochloride : 0,56 mg/ml	60		3401



Facteur influençant la stabilité

	PVC			507 1832
	PVQ			514



Compatibilités

	Fentanyl citrate : 50 µg/ml Aciclovir sodium : 5 mg/ml		2335
	Fentanyl citrate : 10 µg/ml		4488
	Fentanyl citrate : 40 µg/ml Alprostadil : 20 µg/ml		4651
	Fentanyl citrate : 40 µg/ml Alprostadil : 20 µg/ml		4491
	Fentanyl citrate : 50 µg/ml	RL	4603
	Fentanyl citrate : 10 µg/ml Alprostadil : 15 µg/ml		3201
	Fentanyl citrate : 10 µg/ml Amiodarone hydrochloride : 12,5 mg/ml		4119

		Fentanyl citrate : 10 µg/ml Amiodarone hydrochloride : 0,6 >> 9,75 mg/ml		4119
		Fentanyl citrate : 50 µg/ml Amiodarone hydrochloride : 6 mg/ml		1611
		Fentanyl citrate : 10 µg/ml Amiodarone hydrochloride : 25 mg/ml		4119
		Fentanyl citrate : 50 µg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Fentanyl citrate : 50 µg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Fentanyl citrate : 50 µg/ml Ampicillin sodium : 20 mg/ml		63
		Fentanyl citrate : 50 µg/ml Anidulafungin : 0.5 mg/ml		1982
		Fentanyl citrate : 500 µg/ml Argatroban : 1 mg/ml		1964
		Fentanyl citrate : 25 µg/ml Atropine sulfate : 0.4 mg/ml		1974
		Fentanyl citrate : 50 µg/ml		3948
		Fentanyl citrate : 10 µg/ml Atracurium besylate : 0.5 mg/ml		402
		Fentanyl citrate : 50 µg/ml Azithromycine : 2 mg/ml		1800
		Fentanyl citrate : 50 µg/ml Bivalirudin : 5 mg/ml		1944
		Fentanyl citrate : 50 µg/ml Bivalirudin : 5 mg/ml		1713
		Fentanyl citrate : 25 µg/ml Bupivacaine hydrochloride : 20 mg/ml		3131
		Fentanyl citrate : 20 µg/ml Bupivacaine hydrochloride : 1,250 mg/ml		60
		Fentanyl citrate : 50 µg/ml Caffeine : 10 mg/ml		3964
		Fentanyl citrate : 50 µg/ml Calcium gluconate : 100 mg/ml		63
		Fentanyl citrate Calcium gluconate		3644
		Fentanyl citrate : 50 µg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Fentanyl citrate : 50 µg/ml Caspofungin acetate : 0.5 mg/ml		2233
		Fentanyl citrate : 50 µg/ml Cefazolin sodium : 20 mg/ml		3380
		Fentanyl citrate : 50 µg/ml Cefazolin sodium : 20 mg/ml		63
		Fentanyl citrate : 50 µg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Fentanyl citrate : 50 µg/ml Cefotaxime sodium : 20 mg/ml		63
		Fentanyl citrate : 50 µg/ml Ceftaroline fosamil : 2,22 mg/ml		3249

	Fentanyl citrate : 50 µg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
	Fentanyl citrate : 50 µg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
	Fentanyl citrate : 50 µg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
	Fentanyl citrate : 50 µg/ml Cefuroxime sodium : 30 mg/ml		3380
	Fentanyl citrate : 1 µg/ml		821
	Fentanyl citrate : 50 µg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
	Fentanyl citrate : 50 µg/ml		316
	Fentanyl citrate : 50 µg/ml Cefuroxime sodium : 15 mg/ml		63
	Fentanyl citrate : 12.5 µg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
	Fentanyl citrate : 50 µg/ml		3948
	Fentanyl citrate : 50 µg/ml Cimetidine hydrochloride : 150 mg/ml		1438
	Fentanyl citrate : 50 µg/ml Cimetidine hydrochloride : 15 mg/ml		63
	Fentanyl citrate Cisatracurium besylate		3601
	Fentanyl citrate : 50 µg/ml Clindamycin phosphate : 9 mg/ml		63
	Fentanyl citrate : 12.5 & 50 µg/ml		301
	Fentanyl citrate : 50 µg/ml Clonidine hydrochloride : 0,018 mg/ml		2018
	Fentanyl citrate : 50 µg/ml Cloxacillin sodium : 100 mg/ml		3012
	Fentanyl citrate : 50 µg/ml Dexamethasone sodium phosphate : 4 mg/ml		63
	Fentanyl citrate : 25 µg/ml Dexamethasone sodium phosphate : 1 mg/ml		1974
	Fentanyl citrate : 25 µg/ml Diazepam : 0.5 mg/ml		1974
	Fentanyl citrate : 50 µg/ml Digoxin : 100 µg/ml		63
	Fentanyl citrate : 50 µg/ml Diltiazem hydrochloride : 1 mg/ml		314
	Fentanyl citrate : 25 µg/ml Diphenhydramine hydrochloride : 2 mg/ml		1974
	Fentanyl citrate : 30 µg/ml Dobutamine hydrochloride : 8 mg/ml		1506
	Fentanyl citrate : 50 µg/ml Dobutamine hydrochloride : 4 mg/ml		314
	Fentanyl citrate : 50 µg/ml Dobutamine hydrochloride : 2 mg/ml		63
	Fentanyl citrate : 30 µg/ml Dopamine hydrochloride : 8 mg/ml		1506

	Fentanyl citrate : 50 µg/ml Dopamine hydrochloride : 1,6 mg/ml		63
	Fentanyl citrate : 50 µg/ml Dopamine hydrochloride : 3.2 mg/ml		314
	Fentanyl citrate : 50 µg/ml Doripenem : 5 mg/ml		2262
	Fentanyl citrate : 25 µg/ml Doxapram hydrochloride : 2 mg/ml		1802
	Fentanyl citrate : 2 µg/ml Enalaprilate : 0.05 mg/ml		1315
	Fentanyl citrate : 50 µg/ml Eravacycline : 0,6 mg/ml		4434
	Fentanyl citrate : 25 µg/ml Esmolol hydrochloride : 5 mg/ml		8
	Fentanyl citrate : 12.5 & 50 µg/ml		1415
	Fentanyl citrate : 50 µg/ml Epinephrine hydrochloride : 20 µg/ml		314
	Fentanyl citrate : 25 µg/ml Esmolol hydrochloride : 5 mg/ml		8
	Fentanyl citrate : 30 µg/ml Esomeprazole sodium : 0.32 mg/ml		1506
	Fentanyl citrate : 50 µg/ml Etomidate : 2 mg/ml		319
	Fentanyl citrate : 12.5 µg/ml Fenoldopam mesylate : 80 µg/ml		1803
	Fentanyl citrate : 12.5 µg/ml Fluorouracil : 1 & 16 mg/ml		514
	Fentanyl citrate : 50 µg/ml Fosfomycin : 30 mg/ml		4055
	Fentanyl citrate : 50 µg/ml Furosemide : 10 mg/ml		314
	Fentanyl citrate : 50 µg/ml Furosemide : 10 mg/ml		63
	Fentanyl citrate : 50 µg/ml Gentamicin sulfate : 10 mg/ml		63
	Fentanyl citrate : 50 µg/ml Glycerophosphate disodium		4332
	Fentanyl citrate Glycopyrronium bromide		3599
	Fentanyl citrate : 25 µg/ml Haloperidol lactate : 0.2 mg/ml		1974
	Fentanyl citrate : 50 µg/ml Heparin sodium : 1 UI/ml	RL	1228
	Fentanyl citrate : 50 µg/ml Heparin sodium : 100 UI/ml		4389
	Fentanyl citrate : 50 µg/ml Heparin sodium : 100 UI/ml		314
	Fentanyl citrate : 50 µg/ml Heparin sodium : 1 UI/ml		1228
	Fentanyl citrate : 12.5 µg/ml Hetastarch : 60 mg/ml		1721

	Fentanyl citrate : 50 µg/ml Hydrocortisone sodium succinate : 1 mg/ml	RL	1228
	Fentanyl citrate : 50 µg/ml Hydrocortisone sodium succinate : 1 mg/ml		1228
	Fentanyl citrate : 50 µg/ml Hydromorphone hydrochloride : 1 mg/ml		314
			3932
	Fentanyl citrate : 25 µg/ml Hydroxyzine dihydrochloride : 4 mg/ml		1974
	Fentanyl citrate : 50 µg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
	Fentanyl citrate : 5, 25 & 50 µg/ml Insulin aspart : 1 UI/ml		1508
	Fentanyl citrate : 50 µg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
	Fentanyl citrate : 9,8 µg/ml Ketamine hydrochloride : 0,19 mg/ml		4436
	Fentanyl citrate : 40 µg/ml Ketamine hydrochloride : 1 mg/ml		1934
	Fentanyl citrate : 25 µg/ml Ketorolac tromethamine : 1 mg/ml		1974
	Fentanyl citrate : 10 µg/ml Labetalol hydrochloride : 1 mg/ml		386
	Fentanyl citrate : 50 µg/ml Labetalol hydrochloride : 2 mg/ml		314
	Fentanyl citrate : 50 µg/ml Lansoprazole : 0.55 mg/ml		1625
	Fentanyl citrate : 2 µg/ml Levobupivacaine hydrochloride : 1.27 mg/ml		2225
	Fentanyl citrate : 4 µg/ml Levobupivacaine hydrochloride		3507
	Fentanyl citrate : 50 µg/ml Levofloxacin : 5 mg/ml		1072
	Fentanyl citrate : 50 µg/ml Levosimendan : 2,5 mg/ml		4389
	Fentanyl citrate : 50 µg/ml Linezolid : 2 mg/ml		1925
	Fentanyl citrate : 50 µg/ml Lorazepam : 0.5 mg/ml		314
	Fentanyl citrate : 50 µg/ml Lorazepam : 0.33 mg/ml		186
	Fentanyl citrate : 25 µg/ml Lorazepam : 0.1 mg/ml		1974
			4034
	Fentanyl citrate : 50 µg/ml Meropenem : 50 mg/ml		4319
			3503
	Fentanyl citrate : 25 µg/ml Metoclopramide hydrochloride : 5 mg/ml		1974

	Fentanyl citrate : 50 µg/ml Metronidazole : 5 mg/ml		63
	Fentanyl citrate : 33.33 µg/ml Midazolam hydrochloride : 1.67 mg/ml		404
	Fentanyl citrate : 50 µg/ml Midazolam hydrochloride : 2 mg/ml		314
	Fentanyl citrate : 13 & 38 µg/ml Midazolam hydrochloride : 0,66 & 0,9 mg/ml		929
	Fentanyl citrate : 25 µg/ml Midazolam hydrochloride : 0.2 mg/ml		1974
	Fentanyl citrate : 50 µg/ml Midazolam hydrochloride : 1 mg/ml		176
	Fentanyl citrate : 20 & 40 µg/ml Midazolam hydrochloride : 0.1 & 0.5 mg/ml		225
	Fentanyl citrate : 50 µg/ml Midazolam hydrochloride : 5 mg/ml		186
	Fentanyl citrate : 50 µg/ml Milrinone lactate : 0.2 mg/ml		314
	Fentanyl citrate : 100 µg/ml Milrinone lactate : 0.8 mg/ml		813
	Fentanyl citrate : 50 µg/ml Morphine sulfate : 2 mg/ml		314
			3766
	Fentanyl citrate : 50 µg/ml Nafamostat : 10 mg/mL		4545
	Fentanyl citrate : 50 µg/ml Nafcillin sodium : 33 mg/ml		1366
			3503
	Fentanyl citrate : 50 µg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
	Fentanyl citrate : 50 µg/ml Nicardipine hydrochloride : 1 mg/ml		314
	Fentanyl citrate : 2 µg/ml Nicardipine hydrochloride : 0.1 mg/ml		1490
	Fentanyl citrate : 50 µg/ml Nitroglycerin : 0,2 mg/ml		63
	Fentanyl citrate : 50 µg/ml Nitroglycerin : 0.4 mg/ml		314
	Fentanyl citrate : 50 µg/ml Norepinephrine bitartrate : 0.128 mg/ml		314
	Fentanyl citrate : 30 µg/ml Norepinephrine bitartrate : 0.32 mg/ml		1506
	Fentanyl citrate : 16.7 µg/ml Ondansetron hydrochloride : 1.33 mg/ml		815
	Fentanyl citrate : 50 µg/ml Oritavancin : 0.8 >>2 mg/ml		3152
	Fentanyl citrate : 50 µg/ml Oxaliplatin : 0,5 mg/ml		1662
	Fentanyl citrate : 50 µg/ml Palonosetron hydrochloride : 50 µg/ml		2196

		Fentanyl citrate : 10 µg/ml Pancuronium bromide : 0.05 mg/ml		402
		Fentanyl citrate Pantoprazole sodium		2090
		Fentanyl citrate : 30 µg/ml Pantoprazole sodium : 0.32 mg/ml		1506
		Fentanyl citrate : 50 µg/ml Paracetamol : 10 mg/ml		4435
		Fentanyl citrate : 50 µg/ml Paracetamol : 10 mg/ml		3571
		Fentanyl citrate : 50 µg/ml Paracetamol : 10 mg/ml		4742
		Fentanyl citrate Pentobarbital sodium		3503
		Fentanyl citrate : 25 µg/ml Phenobarbital sodium : 2 mg/ml		1974
		Fentanyl citrate : 25 µg/ml Phenytoin sodium : 2 mg/ml		1974
		Fentanyl citrate : 50 µg/ml Plazomicin sulfate : 24 mg/ml		4145
		Fentanyl citrate : 50 µg/ml Potassium chloride : 40 mEq/l	RL	1228
		Fentanyl citrate : 50 µg/ml Potassium chloride : 40 mEq/l		1228
		Fentanyl citrate : 50 µg/ml Propofol : 2 mg/ml		319
		Fentanyl citrate : 50 µg/ml Propofol : 10 mg/ml		300
		Fentanyl citrate : 50 µg/ml Propofol		4524
		Fentanyl citrate : 10 & 50 µg/ml Propofol : 10 & 20 mg/ml		2325
		Fentanyl citrate : 50 µg/ml Ranitidine hydrochloride : 1 mg/ml		314
		Fentanyl citrate : 50 µg/ml Ranitidine hydrochloride : 25 mg/ml		58
		Fentanyl citrate : 50 µg/ml Remdesivir : 1 mg/ml		4768
		Fentanyl citrate : 12.5 µg/ml Remifentanyl hydrochloride : 25 & 250 µg/ml		59
		Fentanyl citrate : 50 µg/ml Remimazolam : 5 mg/ml		4723
		Fentanyl citrate : 1 >> 10 µg/ml Ropivacain hydrochloride : 1 - 2 mg/ml		1516
		Fentanyl citrate : 3 µg/ml Ropivacain hydrochloride : 1,5 mg/ml		1832
		Fentanyl citrate : 1 & 10 µg/ml Ropivacain hydrochloride : 1 & 2 mg/ml		1665
		Fentanyl citrate : 50 µg/ml Salbutamol sulfate : 1 mg/ml		3216
		Fentanyl citrate : 50 µg/ml Sargramostim : 6 §15 µg/ml		891

	Fentanyl citrate : 25 µg/ml Scopolamine hydrobromide : 0.05 mg/ml		1974
	Fentanyl citrate : 50 µg/ml Sodium bicarbonate : 84 mg/ml		63
	Fentanyl citrate : 50 µg/ml Sugammadex : 100 mg/ml		3372
	Fentanyl citrate : 0,05 µg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
	Fentanyl citrate : 50 µg/ml Tedizolid phosphate : 0.8 mg/ml		3827
	Fentanyl citrate : 50 µg/ml Theophylline : 1,6 mg/ml		63
	Fentanyl citrate : 50 µg/ml Thiopental sodium : 25 mg/ml		314
	Fentanyl citrate : 50 µg/ml Thiopental sodium : 25 mg/ml		319
	Fentanyl citrate Thiopental sodium		3503
	Fentanyl citrate : 50 µg/ml Thiopental sodium : 25 mg/ml		3767
	Fentanyl citrate : 50 µg/ml Tobramycin sulfate : 10 mg/ml		63
	Fentanyl citrate : 50 µg/ml Vancomycin hydrochloride : 5 mg/ml		63
	Fentanyl citrate : 10 µg/ml Vecuronium bromide : 0.1 mg/ml		402
	Fentanyl citrate : 50 µg/ml Vecuronium bromide : 1 mg/ml		314



Voie d'administration



Bibliographie

	Type	Source
8	Revue	Karnatz NN, Wong J, Kesler H, Baaske DM, Speicher ER. Compatibility of esmolol hydrochloride with morphine sulfate and fentanyl citrate during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 368-371.
58	Revue	Parker WA. Physical compatibility of ranitidine HCl with preoperative injectable medications. Can J Hosp Pharm 1985 ; 38: 160-161.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.

60	Revue	Tu YH, Stiles ML, Allen LV Jr. Stability of fentanyl citrate and bupivacaine hydrochloride in portable pump reservoirs. Am J Hosp Pharm 1990 ; 47: 2037-2040.
63	Revue	Marquardt Ed, Lam SSY. Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 811-812.
176	Revue	Mantong ML, Marquardt ED. Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
186	Revue	Swart EL, Mooren RAG, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
217	Revue	Allen LV, Stiles ML, Wang DP, Tu YH. Stability of bupivacaine hydrochloride, epinephrine hydrochloride, and fentanyl citrate in portable infusion-pump reservoirs. Am J Hosp Pharm 1993 ; 50: 714-715.
222	Revue	Allen LV, Stiles ML, Tu YH. Stability of fentanyl citrate in 0.9% sodium chloride solution in portable infusion pumps. Am J Hosp Pharm 1990 ; 47: 1572-1574.
223	Revue	Kowalski SR, Gourlay GK. Stability of fentanyl citrate in glass and plastic containers and in a patient-controlled delivery system. Am J Hosp Pharm 1990 ; 47: 1584-1587.
225	Revue	Bhatt-Mehta V, Johnson CE, Leininger N, Agarwal M. Stability of fentanyl citrate and midazolam hydrochloride during simulated intravenous coadministration. Am J Health-Syst Pharm 1995 ; 52: 511-513.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
314	Revue	Chiu MF, Schwartz ML. Visual compatibility of injectable drugs used in the intensive care unit. Am J Health-Syst Pharm 1997 ; 54: 64-65.
316	Revue	Veltri M, Lee CKK. Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs. Am J Health-Syst Pharm 1996 ; 53: 2611-2613.
319	Revue	Hadzija BW, Lubarsky DA. Compatibility of etomidate, thiopental sodium, and propofol injections with drugs commonly administered during induction of anesthesia. Am J Health-Syst Pharm 1995 ; 52: 997-999.
386	Revue	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358.
402	Revue	Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821.

404	Revue	Forman JK, Souney PF. Visual compatibility of midazolam hydrochloride with common preoperative injectable medications. Am J Hosp Pharm 1987 ; 44: 2298-2299.
507	Revue	Dawson PJ, Bjorksten AR, Duncan IP, Barnes RK, Beemer GH. Stability of fentanyl, bupivacaine and adrenaline solutions for extradural infusion. Br J Anaesth 1992 ; 68: 414-417.
514	Revue	Xu QA, Trissel LA, Martinez JF. Rapid loss of fentanyl citrate admixed with fluorouracil in polyvinyl chloride containers. Ann Pharmacotherapy 1997 ; 31: 297-302.
813	Revue	Akkermann SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health-Syst Pharm 1999 ; 56: 63-68.
815	Revue	Stewart JT, Warren FW, King DT, Venkateshwaran TG, Fox JL. Stability of ondansetron hydrochloride and 12 medications in plastic syringes. Am J Health-Syst Pharm 1998 ; 55: 2630-2634.
821	Revue	Moshfeghi M, Ciuffo JD. Visual compatibility of fentanyl citrate with parenteral nutrient solutions. Am J Health-Syst Pharm 1998 ; 55: 1194,1197.
891	Revue	Matsuura G. Visual compatibility of sargramostim (GM-CSF) during simulated Y-site administration with selected agents. Hosp Pharm 1992 ; 27: 200, 202, 209.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
929	Revue	Wilson KM, Schneider JJ, Ravenscroft PJ. Stability of midazolam and fentanyl in infusion solutions. J Pain Symptom Manage 1998 ; 16: 52-58.
1072	Revue	Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1228	Revue	Allen LV, Stiles ML. Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2. Am J Hosp Pharm 1981 ; 38: 380-381.
1315	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1366	Revue	Jeglum EL, Winter E, Kotos M. Nafcillin sodium incompatibility with acidic solutions. Am J Hosp Pharm 1981 ; 38: 462,464.
1405	Revue	Peterson GM, Miller KA, Galloway JG, Dunne PF. Compatibility and stability of fentanyl admixtures in polypropylene syringes. J Clin Pharm Ther 1998 ; 23: 67-72.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1438	Revue	Souney PF, Solomon MA, Stancher D. Visual compatibility of cimetidine hydrochloride with common preoperative injectable medications. Am J Hosp Pharm 1984 ; 41: 1840-1841.
1490	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.

1506	Revue	Lopez-Cabezas C, Guerrero L, Molas G, Anglada H, Soy D. Physicochemical compatibility of high concentration drugs usually Y-site administered in intensive care units. EJHP 2015 ;22:107-112.
1508	Revue	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1516	Laboratoire	Ropivacaine (Naropeine®) - Summary of Product Characteristics Mercury Pharmaceuticals Limited 2012
1611	Revue	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Revue	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1665	Revue	Öster Svedberg K, McKenzie J, Larrivee-Elkins C. Compatibility of ropivacaine with morphine, sufentanil, fentanyl, or clonidine. J Clin Pharm Ther 2002 ; 21: 39-45.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1723	Revue	Sattler A, Jage J, Krämer I. Physico-chemical stability of infusion solutions for epidural administration containing fentanyl and bupivacaine or lidocaine. Pharmazie 1998 ; 53: 386-391.
1800	Revue	Voytilla KL, Tyler LS, Rusho WJ. Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery. Am J Health-Syst Pharm 2002 ; 59: 853-855.
1802	Revue	Bell MS, Nolt DH. Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery. Am J Health-Syst Pharm 2003 ; 60: 193-194.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1832	Revue	Hartmann M, Knoth H, K?ler W, Meissner W. Stability of fentanyl/ropivacain preparations for epidural application. Pharmazie 2003 ; 6
1863	Revue	Isert PR, Lee D, Naidoo D, Carasso ML, Kennedy RA. Compatibility of propofol, fentanyl, and vecuronium mixtures designed for potential use in anesthesia and patient transport. Journal of clinical anesthesia 1996 ; 8: 329-336.
1875	Revue	Kjonnixsen I, Brustugun J, Breivik H, Anderssen E, Klem W. Stability of an epidural analgesic solution containing adrenaline, bupivacaine and fentanyl. Acta Anaesthesiol Scand 2000 ; 44: 864-867.

1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1934	Revue	Ambados F, Brealey J. Compatibility of ketamine hydrochloride and fentanyl citrate in polypropylene syringes. Am J Health-Syst Pharm 2004 ; 61: 1438-1445.
1944	Revue	Hartman CA, Faria CE, Mago K. Visual compatibility of bivalirudin with selected drugs. Am J Health-Syst Pharm 2004 ; 61: 1774.
1964	Revue	Hartman CA, Baroletti SA, Churchill WW et al. Visual compatibility of argatroban with selected drugs. Am J Health-Syst Pharm 2002 ; 59: 1784-1785.
1974	Revue	Chandler SW, Trissel LA, Weinstein SM Combined administration of opioids with selected drugs to manage pain and other cancer symptoms initial safety screening for compatibility. J Pain Symptom Manage 1996 ; 12, 3: 168-171.
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
1993	Revue	Lee DKT, Wang DP, Harsono R, Wong CY. Compatibility of fentanyl citrate, ketamine hydrochloride, and droperidol in 0.9% sodium chloride injection stored in polyvinyl chloride bags. Am J Health-Syst Pharm 2005 ; 62: 1190-1192.
2018	Revue	Veggeland T. Visual compatibility of clonidine with selected drugs. Am J Health-Syst Pharm 2005 ; 62: 1968-1969.
2031	Revue	Donnelly RF. Chemical stability of fentanyl in polypropylene syringes and polyvinylchloride bags. Int J Pharm Compound 2005 ; 9: 482-483.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2118	Revue	Chapalain-Pargade S, Laville I, Paci A, Chachaty E, Mercier L, Bourget Ph. Microbiological and physicochemical stability of fentanyl and sufentanil solutions for patient-controlled delivery-systems. J Pain Symptom Manage 2006 ; 32, 1: 90-97.
2196	Revue	Trissel LA, Trusley C, Ben M, Kupiec TC. Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during Y-site administration. Am J Health-Syst Pharm 2007 ; 64, 11: 1209-1213.
2225	Revue	Sacco R, Sacchetto G, Francalanci M, Boselli C. Studio di stabilità chimico-fisica di una formulazione per la terapia antalgica a base di levobupivacaina e fentanyl. Bolletino SIFO 2006 ; 77:81
2233	Revue	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.

2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2280	Revue	Shields DE, Aclan J, Szatkowski A. Chemical stability of admixtures combining ziconotide with fentanyl or sufentanil during simulated intrathecal administration. Int J Pharm Compound 2008 ; 12, 5: 463-466.
2306	Revue	Priston M.J, Hughes J.M, Santillo M, Christie I.W. Stability of an epidural analgesic admixture containing epinephrine, fentanyl and bupivacaine. Anaesthesia 2004 ; 59, 10: 979-983.
2325	Revue	Nemec K, Germ E, Schulz-Siegmund M, Ortner A. The effect of nimodipine, fentanyl and remifentanyl intravenous products on the stability of propofol emulsions. Pharmazie 2009 ; 64, 2: 94-97.
2334	Revue	McCluskey S.V, Graner K.K, Kemp J, Aloumanis V, Ben M, Kupiec T, Nicole Vu N. Stability of fentanyl 5 µg/mL diluted with 0.9% sodium chloride injection and stored in polypropylene syringes Am J Health-Syst Pharm 2009 ; 66, 9: 860-863.
2335	Revue	Canann D, Tyler L.S, Barker B, Condie C. Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients Am J Health-Syst Pharm 2009 ; 66, 8: 727-729
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3131	Revue	Donnelly RF, Wong K, Spencer J. Physical compatibility of high-concentration bupivacaine with hydromorphone, morphine and fentanyl. Can J Hosp Pharm 2010 ; 63, 2: 154-155.
3152	Revue	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3201	Revue	Dice JE. Physical compatibility of alprostadil with commonly used IV solutions and medications in the neonatal intensive care unit. J Pediatr Pharmacol Ther 2006 ; 11:233?6.
3216	Revue	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3372	Revue	Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anesthesiol 2013 ; 63, 1: 163-166.
3380	Revue	Eckle V-S, Heim E, Hahn M, Grasshoff C. Incompatibility of Piritramide with Cephalosporins. Ann Pharmacotherapy 2013 ;47:426-427.
3401	Revue	Helin-Tanninen, M., Lehtonen, M., Naaranlahti, T., Ven?inen, T., Pentik?inen, J., Laatikainen, A., Kokki, H. Stability of an epidural analgesic admixture of levobupivacaine, fentanyl and epinephrine. J Clin Pharm Ther 2013 ;38, 2: 104-108

3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3503	Laboratoire	Fentanyl - Summary of product Characteristics Hameln Pharmaceuticals 2012
3507	Laboratoire	Chirocaine - Summary of Product Characteristics AbbVie 2013
3571	Revue	Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M. Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration. Hosp Pharm 2014 ; 49, 1: 42-47.
3599	Laboratoire	Glycopyrrolate Injection U.S.P. - Summary of Product Characteristics Amco Amdipharm Mercry 2013
3601	Laboratoire	Cisatracurium Actavis - Résumé des Caractéristiques du Produit Actavis 2012
3644	Laboratoire	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3766	Revue	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Revue	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftazolidime/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavanazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3916	Revue	Donnelly R F. Stability of Fentanyl Citrate in Polyolefin Bags. Int J Pharm Compound 2016 ; 20, 6 : 514-516.
3932	Laboratoire	Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit Serb Laboratoire 2015
3948	Revue	Bouchoud L, Fonzo-Christe C, Klingmüller M, Bonnabry P . Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation. JPEN 2012 ;30. 416-424.
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4034	Revue	Chen F-C, Fang B-X, Li P, Zheng F, Shi X-Y. Compatibility and stability of lornoxicam with morphine, tramadol or fentanyl in infusion solutions. Afr J Pharm Pharmacol 2012 ;27,6:2055-2060
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44

4119	Poster	Marcoz N, Ing H, Sautter AM, Saadi JF, Roulin JF, Bonnabry P. Stabilité et compatibilité de solutions injectables d'amiodarone (Cordarone®) Hôpitaux Universitaire de Genève 2004
4145	Revue	Asempta T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4223	Poster	Riss V, Hook R, Neault A, Scharrer E, Law s, Walker S.E. Stability of 20,40 and 50 microg/mL Fentanyl Solutions Stored in Syringes at Room Temperature (23°C). Prof Practice Conference - Canadian Society of PH 2019
4228	Poster	Law S, Perks W, Iazetta J, Walker S. Stability of 10 and 50 microg/mL Fentanyl Solutions in CADD Reservoirs, PVC containers and Ethylene/Propylene Co-Polymer (PAB) Bags at Refrigerated (4°C) and Room Temperature (23°C). Prof Practice Conference - Canadian Society of PH 2017
4303	Revue	Anderson C, MacKay M. Stability of Fentanyl Citrate, Hydromorphone Hydrochloride, Ketamine Hydrochloride, Midazolam, Morphine Sulfate, and Pentobarbital Sodium in Polypropylene Syringes. Pharmacy 2015 3, 379-385.
4319	Revue	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4332	Poster	Compatibilité de Glycophos® avec d'autres médicaments administrés en perfusion aux soins intensifs (SI) Compatibilité de Glycophos® avec d'autres médicaments administrés en perfusion aux soins intensifs (SI). JFSPH 2019 2019
4389	Revue	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4433	Revue	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4434	Revue	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4435	Revue	Hanifah S, Nugroho B.H, Chabib L. Compatibility of acetaminophen with central nervous system medications during simulated Y-site injection. Anaesthesiol Intensive Ther 2020 ; 52, 1: 23-27.
4436	Revue	Hanifah S, Kennedy R.A; Ball P.A. Extended compatibility of fentanyl and ketamine in dextrose 5%. Anaesthesiol Intensive Ther 2018 ; 50, 3: 221-225.
4488	Revue	Nezvalova-Henriksen K, Niklas Nilsson N, Tomine Østerberg C, Staven Berge V, Tho I. Y-Site Physical Compatibility of Numeta G13E with Drugs Frequently Used at Neonatal Intensive Care. Pharmaceutics 2020 ; 12, 677.
4491	Revue	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pilar P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2020
4524	Poster	Stucki C, Sautter A-M, Bonnabry P. Physical compatibility of the propofol emulsion with 33 drugs used in anaesthesiology. ESCP Symposium, Geneva, Switzerland 2009
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61

4545	Revue	Kondo M, Nagano M, Yoshida M, Yoshida N, Tagui N, Yoshida M, Sugaya K, Takase H. Physical compatibility of nafamostat with analgesics, sedatives, and muscle relaxants for coronavirus disease treatment. Journal of Nippon Medical school 2021
4559	Revue	Chen P, Chen F, Lei J, Zhou B. Physical Compatibility and Chemical Stability of Fentanyl and Naloxone Hydrochloride in 0.9% Sodium Chloride Injection Solution for Patient-Controlled Analgesia Administration. Drug Design Dev Ther 2020 ;14, 4179-4187.
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4651	Revue	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pascual P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2021 ;180,1169–1176.
4666	Revue	Lee C.H, Kim A.R, Lee M.K, Oh J.S, Lee D.K, Choi S.S. Intravenous patient-controlled analgesia: in vitro stability profiles of mixtures containing fentanyl, hydromorphone, oxycodone, nefopam, ondansetron, and ramosetron. J Anal Sci Tech 2020 ; 11: 32.
4723	Revue	Kondo M, Yoshida N, Yoshida M, Tanaka C, Tagami T, Horik K, Sugaya K, Takase H Physical compatibility of remimazolam with opioid analgesics, sedatives, and muscle relaxants during simulated Y-site administration. Am J Health-Syst Pharm 2022 https://doi.org/10.1093/a
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilit� physique de l'ac�tamino ph�ne injectable avec 102 autres m�dicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4768	Revue	Kondo M, Genpei M, Watanabe K, Yoshida M, Tagui N, Fukao S, Sugaya K, Takase H. Y-site injection physical compatibility of remdesivir with select intravenous drugs used in palliative care and for treating coronavirus disease 2019. Journal of Nippon Medical school 2023
4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:



Dictionnaire

	Antalgique		Injectable
	Noms commerciaux		Stabilité des solutions
	Contenant		Molécule
	Concentration		Température
	Conservation		Durée de stabilité
	Biosimilaire		Données conflictuelles
	Bibliographie		Verre
	NaCl 0,9% ou glucose 5%		Lumière
	Heure		Polyvinyl chlorure
	Chlorure de sodium 0,9%		Non précisée
	Jour		Aucun
	A l'abri de la lumière		Polyoléfine
	Seringue polypropylène		Stabilité en mélange
	Solvant		Molécule
	Avec ou sans lumière		Glucose 5%
	Non précisé		Polypropylène
	Ethylène vinyl acétate		Eau pour préparation injectable
	Elastomère en polyisoprène		Non précisé
	Facteur influençant la stabilité		Provoque
	Adsorption		Compatibilités
	Compatible		Nutrition parentérale (mélange ternaire)
RL	Ringer lactate		Turbidité immédiate
	Incompatible		Précipitation immédiate
	Incompatibilité non précisée		Nutrition parentérale (mélange binaire)
	Instabilité chimique		Solvant spécifique
	Précipitation en 15 minutes		Précipitation en 1 heure
	Voie d'administration		Intraveineuse
	Perfusion continue		Intramusculaire
	Sous cutanée		Perfusion SC continue
	Bibliographie		Dictionnaire